More recently, serum CK19 fragments (Cyfra 21.1) emerged as potentially useful circulating marker in dedifferentiating thyroid cancer despite low or absent CK19 immunostaining in corresponding tumour tissues carcinomas7, 14–16. This evidence concerns the gene KRT19 and neoplasm.